Page 35 of 51: studies 341 to 350 of 509, newest first. Back to the psilocybin for depression overview
Australian & New Zealand Journal of Psychiatry May 3, 2023 Susan L. Rossell, Sally Meikle, M.l. Williams et al. 14 citations
No description available
Biological Psychiatry May 1, 2023 Scott T Aaronson, Tammy Miller, Samuel Rudow et al.
Background: Despite increasingly re fi ned tools for identi-fying individuals at clinical high-risk for psychosis (CHR-P), less is known about the effectiveness of interventions for CHR-P. The signi fi cant clinical heterogeneity among CHR-P individuals is a notable barrier, suggesting that interventions may need to be personalized during this emerging phase of illness. To address these gaps, the...
Journal of Affective Disorders May 1, 2023 Guy M. Goodwin, Megan Croal, Lindsey Marwood et al. 13 citations
Blinding of treatment allocation in clinical trials in psychiatry is regarded as an ideal. The potential impact of unblinding chimes with a general concern for psychological research: so-called demand characteristics can undermine confidence in findings from experimental and clinical studies. Scepticism can result in nihilism. The reliance on subjective report of symptoms in clinical trials of...
Journal of Psychopharmacology April 25, 2023 Brandon Weiss, David Erritzøe, Bruna Giribaldi et al. 24 citations
Background: In a recent clinical trial examining the comparative efficacy of psilocybin therapy (PT) versus escitalopram treatment (ET) for major depressive disorder, 14 of 16 major efficacy outcome measures yielded results that favored PT, but the Quick Inventory of Depressive Symptomatology, Self-Report, 16 items (QIDS-SR 16 ) did not. Aims: The present study aims to (1) rationally and...
JAMA Oncology April 13, 2023 Manish Agrawal, Ezekiel Emanuel, Brian D. Richards et al. 48 citations
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.
Behavioral Sciences March 31, 2023 Jonathan Joseph Dawood Hristova, Virtudes Pérez-Jover 39 citations
Depression is a common mental health issue that affects 280 million people in the world with a high mortality rate, as well as being a leading cause of disability. Psychopharmacological therapies with psychedelics, particularly those with psilocybin, are showing promising potential for the treatment of depression, among other conditions. Some of their benefits include a rapid and exponential...
Journal of Psychopharmacology March 20, 2023 Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al. 153 citations
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with...
March 10, 2023 Mika Turkia 4 citations preprint
In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a reversal of that concept is proposed: psychedelics could be conceptualized as a tool for people chronically anxious and depressed since early childhood to understand ordinary states of mind (e.g. calmness, hopefulness, relaxation, and joy). The case...
March 10, 2023 Mika Turkia 9 citations preprint
While a relatively large body of research exists on many aspects of psychedelic therapy, articles describing a complete, successful treatment process are rarely found. This article therefore presents a case of a woman in her early forties with early complex trauma due to domestic violence, sexual abuse and poverty in her childhood, resulting in approximately three decades of treatment resistant...
Biomedicines March 7, 2023 Hans O. Kalkman 16 citations
Depression is a major public health concern. Unfortunately, the present antidepressants often are insufficiently effective, whilst the discovery of more effective antidepressants has been extremely sluggish. The objective of this review was to combine the literature on depression with the pharmacology of antidepressant compounds, in order to formulate a conceivable pathophysiological process,...